The Effect of Semaglutide on the Intestinal Flora in Obesity

Sponsor
Beijing Chao Yang Hospital
Study ID
NCT07323134
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.

Key Dates

Start date
Feb 1, 2026
Status verified
Jul 2025
Primary completion
Aug 1, 2026
Completion
Aug 1, 2026

Study Design

Enrollment
40 participants (estimated)

Primary Outcome Measure

The composition of the gut microbiota changes relative to the baseline [ Time Frame: Baseline,4weeks,8weeks,12weeks ]

Central Contacts

Related Studies